HCA Healthcare, Inc. $HCA Shares Purchased by Simplicity Wealth LLC

Key Points

• Simplicity Wealth LLC increased its stake in HCA Healthcare by 92.7% in Q2, bringing its total holdings to 1,798 shares valued at approximately $689,000.
• Institutional investors own 62.73% of HCA Healthcare, with significant stakes purchased by firms like Nuveen LLC and Pacer Advisors Inc. in the first quarter.
• HCA Healthcare recently reported earnings of $6.84 EPS, surpassing estimates, and announced a quarterly dividend of $0.72 per share with a yield of 0.7%.

Simplicity Wealth LLC increased its holdings in shares of HCA Healthcare, Inc. (NYSE:HCA - Free Report) by 92.7% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,798 shares of the company's stock after purchasing an additional 865 shares during the period. Simplicity Wealth LLC's holdings in HCA Healthcare were worth $689,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of HCA. Nuveen LLC acquired a new stake in HCA Healthcare during the 1st quarter worth $569,217,000. Pacer Advisors Inc. lifted its stake in shares of HCA Healthcare by 6,237.9% in the 1st quarter. Pacer Advisors Inc. now owns 1,350,933 shares of the company's stock worth $466,815,000 after acquiring an additional 1,329,618 shares during the period. Price T Rowe Associates Inc. MD lifted its stake in shares of HCA Healthcare by 83.4% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 2,399,372 shares of the company's stock worth $829,104,000 after acquiring an additional 1,091,416 shares during the period. Goldman Sachs Group Inc. lifted its stake in shares of HCA Healthcare by 49.1% in the 1st quarter. Goldman Sachs Group Inc. now owns 1,781,459 shares of the company's stock worth $615,583,000 after acquiring an additional 587,036 shares during the period. Finally, Abdiel Capital Advisors LP acquired a new stake in shares of HCA Healthcare in the 1st quarter worth $164,835,000. Institutional investors and hedge funds own 62.73% of the company's stock.

Insider Activity at HCA Healthcare

In other news, EVP Michael S. Cuffe sold 3,836 shares of HCA Healthcare stock in a transaction dated Monday, September 8th. The shares were sold at an average price of $418.84, for a total transaction of $1,606,670.24. Following the completion of the sale, the executive vice president directly owned 31,503 shares in the company, valued at $13,194,716.52. The trade was a 10.85% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 1.30% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on the stock. Cantor Fitzgerald restated an "overweight" rating and issued a $444.00 target price on shares of HCA Healthcare in a research note on Tuesday. Wall Street Zen upgraded shares of HCA Healthcare from a "hold" rating to a "buy" rating in a research note on Saturday, July 5th. Morgan Stanley reduced their price objective on shares of HCA Healthcare from $410.00 to $400.00 and set an "equal weight" rating for the company in a research note on Monday, July 28th. Wolfe Research cut shares of HCA Healthcare from an "outperform" rating to a "peer perform" rating in a research note on Monday, July 28th. Finally, Wells Fargo & Company raised their price objective on shares of HCA Healthcare from $375.00 to $412.00 and gave the company an "equal weight" rating in a research note on Tuesday. One research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and nine have issued a Hold rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $410.83.

HCA Healthcare Trading Up 0.9%

NYSE:HCA opened at $437.46 on Wednesday. The firm has a 50-day moving average price of $401.26 and a two-hundred day moving average price of $374.10. HCA Healthcare, Inc. has a twelve month low of $289.98 and a twelve month high of $439.01. The company has a market capitalization of $102.36 billion, a P/E ratio of 18.39, a price-to-earnings-growth ratio of 1.36 and a beta of 1.40.

HCA Healthcare (NYSE:HCA - Get Free Report) last posted its earnings results on Friday, July 25th. The company reported $6.84 earnings per share for the quarter, beating the consensus estimate of $6.20 by $0.64. The firm had revenue of $18.61 billion during the quarter, compared to the consensus estimate of $18.49 billion. HCA Healthcare had a net margin of 8.21% and a negative return on equity of 7,363.11%. The firm's revenue for the quarter was up 6.4% on a year-over-year basis. During the same period last year, the firm posted $5.50 EPS. HCA Healthcare has set its FY 2025 guidance at 25.500-27.000 EPS. On average, equities research analysts predict that HCA Healthcare, Inc. will post 24.98 earnings per share for the current year.

HCA Healthcare Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Tuesday, September 30th. Stockholders of record on Tuesday, September 16th were issued a dividend of $0.72 per share. The ex-dividend date was Tuesday, September 16th. This represents a $2.88 dividend on an annualized basis and a dividend yield of 0.7%. HCA Healthcare's payout ratio is 12.11%.

HCA Healthcare Profile

HCA Healthcare, Inc, through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. It operates general and acute care hospitals that offers medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.